Raloxifeno [Spanish] en es it fr

Categoria

Raloxifeno [Spanish] Nombres de marca, Raloxifeno [Spanish] Analogos

Raloxifeno [Spanish] Marca los nombres de mezcla

  • No information avaliable
  • Raloxifeno [Spanish] Formula quimica

    C28H27NO4S

    Raloxifeno [Spanish] RX enlace

    http://www.rxlist.com/cgi/generic/raloxif.htm

    Raloxifeno [Spanish] FDA hoja

    Raloxifeno_[Spanish] FDA

    Raloxifeno [Spanish] MSDS (hoja de seguridad de materiales)

    Raloxifeno_[Spanish] MSDS

    Raloxifeno [Spanish] Sintesis de referencia

    CD Jones et al., J. Med. Cem. 27, 1057 (1984)

    Raloxifeno [Spanish] Peso molecular

    473.584 g/mol

    Raloxifeno [Spanish] Punto de fusion

    143-147oC

    Raloxifeno [Spanish] H2O Solubilidad

    0.25 mg / L

    Raloxifeno [Spanish] Estado

    Solid

    Raloxifeno [Spanish] LogP

    5.749

    Raloxifeno [Spanish] Formas de dosificacion

    Tableta

    Raloxifeno [Spanish] Indicacion

    Para la prevención de la osteoporosis en mujeres post-menopáusicas

    Raloxifeno [Spanish] Farmacologia

    El raloxifeno, un modulador selectivo del receptor de estrógeno (SERM) de la clase benzotiofeno, es similar al tamoxifeno, ya que produce efectos similares al estrógeno en el hueso y el metabolismo lipídico, mientras que antagonizar los efectos del estrógeno sobre el tejido mamario. El raloxifeno disminuye la resorción ósea, aumenta la densidad mineral ósea (DMO) y disminuye la incidencia de fracturas. El raloxifeno se utiliza en la prevención de la menopausia la osteoporosis y el cáncer de mama.

    Raloxifeno [Spanish] Absorcion

    Aproximadamente el 60% de una dosis oral se absorbe, pero glucuronoconjugación presistémico es muy amplia. La biodisponibilidad absoluta de raloxifeno es del 2,0%

    Raloxifeno [Spanish] Toxicidad

    No hay información disponible

    Raloxifeno [Spanish] Informacion de Pacientes

    PATIENT INFORMATION

    For safe and effective use of EVISTA, the physician should inform patients about the following:

    Patient Immobilization: EVISTA should be discontinued at least 72 hours prior to and during prolonged immobilization
    (e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of
    movement during travel because of the increased risk of venous thromboembolic events.

    Hot flashes or flushes: EVISTA is not effective in reducing hot flashes or flushes associated with estrogen deficiency.
    In some asymptomatic patients, hot flashes may occur upon beginning EVISTA therapy.

    Other Preventive Measures: Patients should be instructed to take supplemental calcium and vitamin D, if daily dietary
    intake is inadequate. Weight-bearing exercise should be considered along with the modification of certain behavioral
    factors, such as cigarette smoking, and/or alcohol consumption, if these factors exist.

    Physicians should instruct their patients to read the patient package insert before starting therapy with EVISTA and to
    re-read it each time the prescription is renewed.

    Raloxifeno [Spanish] Organismos afectados

    Humanos y otros mamíferos